Q-omics provides the consensus-scored DEFB113 profile across patient tissues and cancer cell-line models. DEFB113 expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in STAD. Additionally, DEFB113 RNA expression shows 8,584 significant gene co-expression associations, with the highest sampling consensus in LUSC. Together, these results highlight STAD, and LUSC as cancer lineages where DEFB113 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFB113 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFB113 survival associations across molecular data types. DEFB113 RNA expression shows survival associations in the most cancer types (6), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFB113 RNA expression–survival associations across cancer types. High DEFB113 expression shows unfavorable associations in STAD, HNSC, PAAD, LUAD, SKCM and SARC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for DEFB113 RNA expression.
This table shows molecular features associated with DEFB113 in patient tissues and cancer cell lines. In patient samples, DEFB113 shows the broadest associations at the RNA and protein expression levels, with LUSC recurring as the lineage with the largest associated feature set. In cancer cell lines, DEFB113 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT.
